spacer
The Healthcare Sales & Marketing Network celebrates 28 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Novartis AG 

 HSMN NewsFeed - 3 Jul 2025
Novartis Provides Update on Phase III GCAptAIN Study of Cosentyx(R) in Giant Cell Arteritis (GCA)
Biopharmaceuticals
 HSMN NewsFeed - 30 Apr 2025
Regulus Therapeutics Enters into Agreement to be Acquired by Novartis AG
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 22 Jul 2024
Latigo Biotherapeutics Appoints Nima Farzan as Chief Executive Officer, Positioning Company for Rapid Growth
Biopharmaceuticals Personnel
 HSMN NewsFeed - 24 Nov 2023
Novartis Issues Voluntary US Nationwide Recall of Two Lots of Sandimmune(R) Oral Solution (cyclosporine oral solution, USP), 100 mg/mL due to Crystallization
Biopharmaceuticals Product Recall
 HSMN NewsFeed - 31 Oct 2023
FDA Approves Novartis Cosentyx(R) as the First New Biologic Treatment Option for Hidradenitis Suppurativa Patients in Nearly a Decade
Biopharmaceuticals FDA
 HSMN NewsFeed - 6 Apr 2022
FDA approves Novartis Vijoice(R) (alpelisib) as first and only treatment for select patients with PIK3CA-Related Overgrowth Spectrum (PROS)
Biopharmaceuticals FDA
 HSMN NewsFeed - 30 Mar 2022
Omega Therapeutics Strengthens Team With Key Management Appointments To Support Its Growth
Biopharmaceuticals Personnel
 HSMN NewsFeed - 16 Jul 2021
Sandoz launches first generic high dose intravenous iron, Ferumoxytol Injection, to treat US patients with iron deficiency anemia
Biopharmaceuticals Generics Product Launch
 HSMN NewsFeed - 22 Mar 2021
Oakrum Pharma and Aucta Pharma Announce U.S. FDA Approval of Generic Version of JADENU(R) Sprinkle (Deferasirox Granules)
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 1 Dec 2020
Novartis announces FDA approval of Xolair(R) (omalizumab) for adults with nasal polyps
Biopharmaceuticals FDA
 HSMN NewsFeed - 5 Jun 2020
Sosei Heptares Notes Phase IIIb ARGON Study With Enerzair(R) Breezhaler(R) (QVM149) Meets Primary Endpoint in Patients With Uncontrolled Asthma
Biopharmaceuticals Drug Delivery
 HSMN NewsFeed - 27 Apr 2020
Cytosorbents Appoints Dr. Efthymios N. Deliargyris, M.D., As Chief Medical Officer
Devices Personnel
 HSMN NewsFeed - 22 Apr 2020
Novartis Kymriah(R) receives FDA Regenerative Medicine Advanced Therapy designation in follicular lymphoma
Biopharmaceuticals Regenerative Medicine Oncology FDA
 HSMN NewsFeed - 11 Feb 2020
Novartis announces MET inhibitor capmatinib (INC280), the first potential treatment for METex14 mutated advanced non-small cell lung cancer, granted priority FDA review
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 27 Mar 2019
Novartis receives FDA approval for Mayzent(R) (siponimod), the first oral drug to treat secondary progressive MS with active disease
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 4 Sep 2018
Genoptix Launches FDA-Authorized BCR-ABL MRDx(R) TFR Monitoring Test for Patients with Chronic Myeloid Leukemia on Tasigna(R) (nilotinib)
Diagnostics Oncology Product Launch
 HSMN NewsFeed - 20 Jul 2018
Alcon introduces NGENUITY(R) 3D Visualization System with DATAFUSION(TM) to simplify, customize vitreoretinal surgery
Devices Ophthalmology Surgery Product Launch
 HSMN NewsFeed - 30 May 2018
FDA expedites review of Novartis drug Promacta(R) for first-line severe aplastic anemia (SAA)
Biopharmaceuticals FDA
 HSMN NewsFeed - 10 May 2018
Aldeyra Therapeutics Appoints David McMullin as Senior Vice President, Corporate Development and Strategy
Biopharmaceuticals Ophthalmology Personnel
 HSMN NewsFeed - 25 Apr 2018
Novartis launches FocalView app, providing opportunity for patients to participate in ophthalmology clinical trials from home
Biopharmaceuticals Ophthalmology Product Launch
 HSMN NewsFeed - 13 Feb 2018
Sandoz announces US FDA approval and launch of Glatopa(R) 40 mg/mL three times-a-week generic option for relapsing forms of multiple sclerosis
Biopharmaceuticals Generics FDA Product Launch
 HSMN NewsFeed - 17 Jan 2018
Novartis granted US FDA Priority Review for Kymriah(TM) (tisagenlecleucel), formerly CTL019, for adults with r/r DLBCL
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 16 Jan 2018
Novartis new data reinforces superiority of Cosentyx(R) versus Stelara(R) in achieving skin clearance for psoriasis patients
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 4 Jan 2018
Novartis drug Promacta(R) receives FDA Breakthrough Therapy designation for first-line use in severe aplastic anemia (SAA)
Biopharmaceuticals FDA
 HSMN NewsFeed - 22 Dec 2017
Novartis' combination therapy Tafinlar(R) + Mekinist(R) granted FDA Priority Review for the adjuvant treatment of stage III BRAF V600 mutation-positive melanoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 18 Dec 2017
Novartis multiple sclerosis therapy fingolimod granted FDA Breakthrough Therapy designation for pediatric MS
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 15 Sep 2017
Janssen Receives CHMP Positive Opinion for Guselkumab Recommending Approval for the Treatment of Moderate to Severe Plaque Psoriasis in the European Union
Biopharmaceuticals Dermatology Regulatory
 HSMN NewsFeed - 11 Jul 2017
Evelo Biosciences Announces $50 Million Series B Financing and Expansion of Board and Leadership Team
Biopharmaceuticals Venture Capital Personnel
 HSMN NewsFeed - 28 Apr 2017
Novartis Receives FDA Approval for Rydapt(R) in Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML) and Three Types of Systemic Mastocytosis (SM)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 18 Apr 2017
Novartis CAR-T cell therapy CTL019 receives FDA Breakthrough Therapy designation for treatment of adult patients with r/r DLBCL
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 24 Feb 2017
CHMP Issues Positive Opinion Recommending DARZALEX(R) (daratumumab) for Relapsed or Refractory Multiple Myeloma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 8 Feb 2017
Genmab Appoints Judith Klimovsky, MD, as Chief Development Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 27 Jan 2017
Pharmaceuticals Veteran George R. Stevenson Joins the GeneriCo Board of Directors
Biopharmaceuticals Generics Personnel
 HSMN NewsFeed - 23 Dec 2016
Alcon receives US FDA approval for AcrySof(R) IQ ReSTOR(R) +3.0D Multifocal Toric intraocular lens for cataract patients
Devices Ophthalmology FDA
 HSMN NewsFeed - 1 Aug 2016
Bioniz Therapeutics Closes Series A Financing and Appoints David Pyott as Chairman of the Board of Directors
Biopharmaceuticals Venture Capital Personnel
 HSMN NewsFeed - 11 May 2016
Pernix Therapeutics Announces CEO Transition
Biopharmaceuticals Personnel
 HSMN NewsFeed - 27 Apr 2016
Novartis Receives Three FDA Breakthrough Therapy Designations for IlaristTo Treat Rare Types of Periodic Fever Syndromes
Biopharmaceuticals FDA
 HSMN NewsFeed - 16 Jan 2016
Novartis receives two new FDA approvals for Cosentyx(R) (secukinumab) to treat patients with ankylosing spondylitis and psoriatic arthritis
Biopharmaceuticals FDA
 HSMN NewsFeed - 15 Oct 2015
GenomeDx Biosciences Adds Tina Nova and Craig Johnson to Board of Directors
Diagnostics Personalized Medicine Oncology Personnel
 HSMN NewsFeed - 24 Jul 2015
FDA approves Novartis drug Odomzo(R) (sonidegib) for locally advanced basal cell carcinoma (laBCC), a form of skin cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 1 Jul 2015
Celldex Therapeutics Appoints Richard Wright as Chief Commercial Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 4 Jun 2015
Ultragenyx Appoints Dennis Huang as Chief Technical Operations Officer and Senior Vice President
Biopharmaceuticals Personnel
 HSMN NewsFeed - 11 May 2015
PaxVax Appoints Nima Farzan Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 16 Dec 2014
Novartis gains FDA approval for Signifor(R) LAR to treat patients with acromegaly, a rare and life-threatening hormonal disorder
Biopharmaceuticals FDA
 HSMN NewsFeed - 30 Jun 2014
Proteostasis Therapeutics Appoints Meenu Chhabra as Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 May 2014
Timothy Maloney appointed President of Novartis Pharmaceuticals Canada Inc.
Biopharmaceuticals Personnel
 HSMN NewsFeed - 29 Apr 2014
Novartis gains FDA approval for Zykadia(TM), first therapy for patients with ALK+ NSCLC previously treated with the ALK inhibitor crizotinib
Biopharmaceuticals Oncology
 HSMN NewsFeed - 7 Apr 2014
Mallinckrodt Pharmaceuticals And Questcor Pharmaceuticals Enter Into Definitive Merger Agreement Under Which Mallinckrodt Will Acquire Questcor For Approximately $5.6 Billion, Creating A Diversified, High-Growth Specialty Pharmaceuticals Company
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 22 Oct 2013
Sideris Pharmaceuticals Completes $32 Million Equity Financing and Signs Agreement With Global Pharmaceutical Company
Biopharmaceuticals Venture Capital Personnel
 HSMN NewsFeed - 30 Jul 2013
Andrea L. Saia Joins Align Technology Board of Directors
Devices Dental Personnel
 HSMN NewsFeed - 11 Jun 2013
Questcor Pharmaceuticals Acquires Rights to Synacthen(R)
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 10 May 2013
Novartis drug Ilaris(R) approved by FDA to treat active systemic juvenile idiopathic arthritis, a serious form of childhood arthritis
Biopharmaceuticals. FDA
 HSMN NewsFeed - 6 Dec 2012
QLT Announces Reduction in Force
Biopharmaceuticals
 HSMN NewsFeed - 28 Nov 2012
Valeant Pharmaceuticals Announces New Management Appointments
Biopharmaceuticals Dermatology Personnel
 HSMN NewsFeed - 24 Sep 2012
QLT Announces Sale of Visudyne(R) to Valeant Pharmaceuticals
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 4 Sep 2012
Higher dose of Novartis drug Exelon(R) Patch approved by FDA for patients with mild to moderate Alzheimer's disease
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 23 Jul 2012
Sandoz completes acquisition of Fougera Pharmaceuticals, positioning Sandoz as #1 in generic dermatology globally
Biopharmaceuticals Dermatology Mergers & Acquisitions
 HSMN NewsFeed - 21 May 2012
GenVec Appoints Cynthia Collins as President and CEO
Biopharmaceuticals Personnel
 HSMN NewsFeed - 16 Apr 2012
QLT Announces the Appointment of Christopher Muller as Chief Commercial Officer
Biopharmaceuticals Ophthalmology Personnel
 HSMN NewsFeed - 19 Mar 2012
QLT Receives Orphan Drug Designation for Visudyne for Treatment of Central Serous Chorioretinopathy
Biopharmaceuticals Ophthalmology FDA
 HSMN NewsFeed - 9 Feb 2012
PaxVax Expands Executive Management Team
Biopharmaceuticals HIV/AIDS Personnel
 HSMN NewsFeed - 1 Feb 2012
FDA approves Novartis drug Gleevec(R) label recommending extending treatment to three years for certain GIST patients after surgery
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 8 Jul 2011
Phase III Trial of Novartis Drug Afinitor(R) Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis
Biopharmaceuticals
 HSMN NewsFeed - 11 Apr 2011
Novartis Therapy Gilenya Reduced the Risk of MS Disability Progression Regardless of Treatment History or Disease Severity, New Analysis Shows
Biopharmaceuticals Neurology
 HSMN NewsFeed - 15 Dec 2010
Alcon and Novartis Agree to Merger Terms
Biopharmaceuticals Ophthalmology Mergers & Acquisitions
 HSMN NewsFeed - 9 Dec 2010
Study Shows Novartis Drug Afinitor(R) Plus Hormonal Therapy Delays Disease Progression in Advanced Metastatic Breast Cancer Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Nov 2010
Study in NEJM Shows Novartis Drug Afinitor(R) Reduces Size of SEGAs, Benign Brain Tumors Associated with Tuberous Sclerosis
Biopharmaceuticals Oncology
 HSMN NewsFeed - 30 Oct 2010
Novartis Drug Afinitor(R) Approved by FDA as First Medication for Children and Adults with a Benign Brain Tumor Associated with Tuberous Sclerosis
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 11 Oct 2010
Phase III Novartis Data Show Potential Benefit of Afinitor(R) Plus Sandostatin(R) LAR Depot in Patients with Advanced Carcinoid Tumors
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Sep 2010
Novartis gains FDA approval for Gilenya, a novel first-line multiple sclerosis treatment shown to significantly reduce relapses and delay disability progression
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 22 Sep 2010
Novartis Drug SOM230 is First Medical Therapy to Show Efficacy in a Phase III Trial in Cushing's Disease, a Debilitating Hormonal Disorder
Biopharmaceuticals
 HSMN NewsFeed - 27 Aug 2010
Novartis receives FDA approval of Tekamlo, a single-pill combination of aliskiren and amlodipine to treat high blood pressure
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 26 Aug 2010
XOMA Appoints Jack L. Wyszomierski to Its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 15 Jul 2010
Endo Pharmaceuticals Completes Acquisition of HealthTronics, Inc.
Biopharmaceuticals Devices Mergers & Acquisitions
 HSMN NewsFeed - 1 Jul 2010
Phase III Study Shows Novartis Drug Afinitor(R) More Than Doubles Time Without Tumor Growth in Advanced Pancreatic NET Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Jun 2010
QLT Announces Final Results From Its RADICAL Study Evaluating Verteporfin PDT (Visudyne(R)) Combination Therapy in Exudative AMD
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 14 Jun 2010
aTyr Pharma Appoints Catharine E. Johnson As Senior Vice President of Business Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 4 Jun 2010
New Data at ASCO Show Novartis Drug Tasigna(R) Surpasses Gleevec(R) for Newly Diagnosed CML Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Jun 2010
Pivotal Phase III Trial of Novartis Drug Afinitor(R) Met Primary Endpoint in Study of Patients With Advanced Pancreatic Neuroendocrine Tumors
Biopharmaceuticals Oncology
 HSMN NewsFeed - 6 May 2010
HealthTronics Enters Into Definitive Merger Agreement With Endo Pharmaceuticals
Devices Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 22 Apr 2010
Novartis Receives US FDA Approval for Zortress(R) (everolimus) to Prevent Organ Rejection in Adult Kidney Transplant Recipients
Biopharmaceuticals FDA
 HSMN NewsFeed - 12 Apr 2010
QLT Names Dipak Panigrahi, M.D., as Chief Medical Officer
Biopharmaceuticals Ophthalmology Personnel
 HSMN NewsFeed - 15 Mar 2010
Timothy Barabe Appointed Chief Financial Officer of Affymetrix
Biopharmaceuticals Personnel
 HSMN NewsFeed - 12 Mar 2010
Endo Pharmaceuticals Announces Appointment of New Chief Operating Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 22 Feb 2010
QLT Names Joseph L. Turner to the Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 22 Feb 2010
FDA Acknowledges Need for Daily Multiple Sclerosis Pill by Granting Fingolimod Priority Review Status
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 19 Feb 2010
Novartis Drug Tasigna(R) Receives FDA Priority Review for Newly Diagnosed Patients With Early-Stage Chronic Myeloid Leukemia
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Jan 2010
Novartis Launches Schizophrenia Treatment Fanapt in the US, Offering Patients an Attractive Alternative to Existing Medications
Biopharmaceuticals
 HSMN NewsFeed - 30 Dec 2009
QLT Acquires Early-Stage Ophthalmic Asset for US$7.5 Million
Biopharmaceuticals Ophthalmology Acquisitions
 HSMN NewsFeed - 9 Dec 2009
6-month results from EVEREST study evaluating Visudyne(R) therapy in patients with polypoidal choroidal vasculopathy
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 8 Dec 2009
Novartis Tasigna(R) Trial Shows Superior Results to Gleevec(R) in Patients With Early-Stage Chronic Myeloid Leukemia
Biopharmaceuticals Oncology
 HSMN NewsFeed - 25 Nov 2009
QLT announces MGH litigation settlement
Biopharmaceuticals Licensing Litigation Ophthalmology
 HSMN NewsFeed - 17 Nov 2009
XOMA Appoints Jim Neal Vice President of Business Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 20 Oct 2009
Novartis drug Tasigna(R) meets primary endpoint in pivotal trial against Gleevec(R) as first-line treatment in chronic myeloid leukemia patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 19 Oct 2009
Endo Pharmaceuticals Gives Update on Regulatory Status of FORTESTA(TM)
Biopharmaceuticals FDA
 HSMN NewsFeed - 19 Oct 2009
QLT restructures Visudyne(R) agreement
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 14 Oct 2009
XOMA Appoints Susan Kramer, Dr. P.H. Vice President of Project and Alliance Management
Biopharmaceuticals Personnel
 HSMN NewsFeed - 12 Oct 2009
Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia
Biopharmaceuticals Licensing
 HSMN NewsFeed - 3 Sep 2009
Endo Pharmaceuticals Introduces VALSTAR(TM) (Valrubicin) To Fill Unmet Need In Aggressive Form of Bladder Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 19 Aug 2009
Results In 'The New England Journal Of Medicine' Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery
Biopharmaceuticals Onology
 HSMN NewsFeed - 21 Jul 2009
FDA Approves Tekturna HCT(R) as Initial Treatment in Patients Unlikely to Achieve Their Blood Pressure Goals With a Single Agent
Biopharmaceuticals FDA
 HSMN NewsFeed - 10 Jul 2009
Bioniche Life Sciences Inc. and Endo Pharmaceuticals Sign Licensing Agreement for Urocidin(TM)
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 15 Jun 2009
QLT announces 12-month results from Novartis sponsored MONT BLANC study evaluating standard-fluence Visudyne(R) combination therapy
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 4 Jun 2009
Xanodyne Announces New President/CEO and Completes $38 Million Equity Financing
Biopharmaceuticals Personnel Venture Capital
 HSMN NewsFeed - 1 Jun 2009
FDA Approves Reclast(R) to Prevent Osteoporosis in Postmenopausal Women With Convenient Less Frequent Dosing
Biopharmaceuticals FDA
 HSMN NewsFeed - 26 May 2009
FDA Grants Full Approval for SPRYCEL (dasatinib) for the Treatment of Adults with Chronic Myeloid Leukemia Who Are Resistant or Intolerant to Prior Therapies Including Gleevec*
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 May 2009
Glivec(R) is the First Adjuvant Treatment Approved in the UK to Delay Return of Gastrointestinal Cancer After Surgery
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 28 Apr 2009
Testosterone Undecanoate Achieves and Maintains Normal Testosterone Levels in Hypogonadal Men With Five Injections Per Year, New Data Show
Biopharmaceuticals
 HSMN NewsFeed - 18 Mar 2009
Gleevec(R) substantially reduces risk of cancer returning in patients with life-threatening gastrointestinal stromal tumors (GIST), The Lancet reports
Biopharmaceuticals Oncology
 HSMN NewsFeed - 28 Jan 2009
Ipsen announces the signature of a co-promotion agreement with Novartis for Exforge in France
Biopharmaceuticals
 HSMN NewsFeed - 15 Jan 2009
XOMA Announces Workforce Reduction
Biopharmaceuticals
 HSMN NewsFeed - 6 Jan 2009
Valeant Pharmaceuticals Appoints Chief Operating Officer of Specialty Pharmaceuticals
Biopharmaceuticals Dermatology Personnel
 HSMN NewsFeed - 11 Dec 2008
New Data Shows Zometa(R) Enhances Impact of Chemotherapy on Reducing Breast Tumour Size
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Dec 2008
Femara(R) (letrozole) FIRST Aromatase Inhibitor to Indicate Overall Survival Benefit Versus tamoxifen When Taken for Five Years After Breast Cancer Surgery
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Nov 2008
Biolex Therapeutics Adds Two Drug Development Executives to Accelerate Development of Locteron(R) in Hepatitis C
Biopharmaceuticals Personnel
 HSMN NewsFeed - 21 Oct 2008
Nektar Sells Pulmonary Business to Novartis For $115 Million and Nektar Retains Key Pulmonary Programs Including Amikacin Inhale, Inhaled Vancomycin, and Ciprofloxacin Inhalation Powder
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 22 Sep 2008
Molecular Insight Pharmaceuticals, Inc. Adds Four Healthcare Industry Experts to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 27 Aug 2008
Gleevec Receives FDA Priority Review as First Therapy to Reduce Recurrence of Gastrointestinal Stromal Tumors After Surgery
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 26 Aug 2008
QLT announces agreement to exclusively license the Atrigel(R) Technology to Reckitt Benckiser Pharmaceuticals Inc.
Biopharmaceuticals Drug Delivery Licensing
 HSMN NewsFeed - 7 Aug 2008
SciClone Pharmaceuticals Appoints Jeffery Lange as Vice President, Business Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Jul 2008
Head-to-Head Study Demonstrates Focalin(R) XR Offers Faster and Better Symptom Control than Concerta(R)1 in Early Part of ADHD Patients' Day
Biopharmaceuticals
 HSMN NewsFeed - 8 Jul 2008
Novartis Completes Purchase of Minority Interest in Alcon
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 8 Jul 2008
Novartis completes acquisition of 25% stake in Alcon from Nestlé, first step toward majority ownership of the world leader in eye care
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 5 Jun 2008
FDA Broadens US Indication for Once-Yearly Reclast(R) as Only Osteoporosis Treatment Approved for Prevention of Fractures After a Hip Fracture
Biopharmaceuticals FDA
 HSMN NewsFeed - 3 Jun 2008
Sunesis Pharmaceuticals Expands Development Leadership Team to Focus on Late-Stage Development of Voreloxin (Formerly SNS-595)
Biopharmaceuticals Personnel
 HSMN NewsFeed - 3 Jun 2008
Sepracor Completes Acquisition of Oryx Pharmaceuticals and Expands Operations in Canada
Biopharmaceuticals
 HSMN NewsFeed - 31 May 2008
Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa(R) in Premenopausal Women With Early-Stage Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 19 May 2008
Launch of Highly Targeted Cancer Treatment Tasigna(R) (nilotinib) Offers Potential Lifeline to Ph+ CML Patients Intolerant or Resistant to Existing Therapies, Including Glivec(R) (imatinib)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 19 May 2008
RAD001 More Than Doubles Time Without Tumor Growth After Failure of Standard Treatment in Patients With Advanced Kidney Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 1 May 2008
Sepracor to Acquire Oryx Pharmaceuticals Inc. and Expand Commercial Operations into Canada
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 17 Apr 2008
Eisai Corporation of North America Announces Appointment of Vice President of U.S. Corporate Communications
Biopharmaceuticals Personnel
 HSMN NewsFeed - 7 Apr 2008
Novartis to further strengthen its healthcare portfolio by acquiring 25% stake in Alcon from Nestlé with right to take over majority ownership of the world leader in eye care
Biopharmaceuticals Ophthalmology Mergers & Acquisitions
 HSMN NewsFeed - 31 Mar 2008
Lotrel, a Single-Pill Combination for Treating High Blood Pressure, Reduced Cardiovascular Events by 20% in High-Risk Patients
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 28 Mar 2008
Positive results from Visudyne(R) combination therapy study reported at Annual Macula Society Conference
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 17 Mar 2008
QLT announces positive FDA action on Aczone(TM)
Biopharmaceuticals
 HSMN NewsFeed - 10 Mar 2008
Femara(R) helps protect against return of breast cancer even when treatment starts several years after completing tamoxifen therapy
Biopharmaceuticals Oncology
 HSMN NewsFeed - 10 Mar 2008
XOMA Appoints Mary L. Anderson as Vice President of Business Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 28 Feb 2008
Everolimus (RAD001) Significantly Extends Progression-Free Survival in Advanced Kidney Cancer Patients After Failure of Other Targeted Therapy
Biopharmaceuticals Oncology
 HSMN NewsFeed - 14 Feb 2008
BiPar Names Hoyoung Huh, M.D., Ph.D. President and Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Feb 2008
Two New Independent Directors Join Chelsea Therapeutics
Biopharmaceuticals Personnel
 HSMN NewsFeed - 18 Jan 2008
QLT reduces workforce as first step in its strategic restructure
Biopharmaceuticals
 HSMN NewsFeed - 12 Dec 2007
Once-Daily Exjade(R) Shown to Remove Toxic Iron From the Heart and Liver, According to Data Presented at ASH
Biopharmaceuticals
 HSMN NewsFeed - 6 Dec 2007
Watson and Novartis Settle Lawsuit Over Exelon(R) Patent Litigation
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 3 Dec 2007
FDA Approves Diovan(R) for Treatment of High Blood Pressure in Children
Biopharmaceuticals FDA
 HSMN NewsFeed - 28 Nov 2007
Tasigna(R) gains European approval for patients with a life-threatening form of leukemia who are resistant or intolerant to existing therapies
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 27 Nov 2007
Zogenix Licenses Exclusive U.S. Commercial Rights for Late Stage, Controlled-Release, Opioid Product from Elan
Biopharmaceuticals Licensing
 HSMN NewsFeed - 26 Nov 2007
Beijing Med-Pharm Announces Exclusive Agreement to Market Enablex(R) in China
Biopharmaceuticals Distribution
 HSMN NewsFeed - 21 Nov 2007
CIBA Vision, the eye care unit of Novartis, announces settlement of patent litigation with CooperVision, Inc.
Devices Ophthalmology Litigation
 HSMN NewsFeed - 21 Nov 2007
Cooper Settles Patent Litigation With CIBA Vision
Devices Ophthalmology Litigation
 HSMN NewsFeed - 8 Nov 2007
FDA Approves New SPRYCEL(R) (Dasatinib) Product Labeling for Patients with Chronic-Phase CML
Biopharmaceuticals FDA Oncology
 HSMN NewsFeed - 29 Oct 2007
Tasigna(R) receives US approval providing new hope to chronic myeloid leukemia patients with resistance or intolerance to existing therapies
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 22 Oct 2007
Voltaren(R) Gel Receives US Regulatory Approval as the First Approved Topical Prescription Treatment for Pain Associated with Osteoarthritis
Biopharmaceuticals Pain Management FDA
 HSMN NewsFeed - 18 Oct 2007
QLT Completes Acquisition of ForSight Newco II, Inc.
Biopharmaceuticals Ophthalmology Drug Delivery
 HSMN NewsFeed - 15 Oct 2007
Sepracor Announces Senior Management Appointments as Part of Commercial Re-Organization
Biopharmaceuticals Personnel
 HSMN NewsFeed - 9 Oct 2007
QLT acquires leading edge ocular drug delivery system from ForSight Labs
Biopharmaceuticals Ophthalmology Drug Delivery
 HSMN NewsFeed - 8 Oct 2007
Steven Engle Appointed Chairman of XOMA
Biopharmaceuticals Personnel
 HSMN NewsFeed - 18 Sep 2007
First Osteoporosis Study in Hip Fracture Patients Finds Once-Yearly Reclast(R) Prevents Additional Fractures and Improves Survival
Biopharmaceuticals
 HSMN NewsFeed - 12 Sep 2007
New Licence for Cubicin(R) (daptomycin), the First in a Novel Class of Antibiotic, is Announced Today for the Treatment of Serious Bloodstream and Heart Infections Caused by the Most Problematic UK Organisms, Including MRSA
Biopharmaceuticals
 HSMN NewsFeed - 31 Aug 2007
Eligard(R) six-month formulation successfully completes European approval procedure
Biopharmaceuticals Drug Delivery Regulatory Oncology
 HSMN NewsFeed - 18 Aug 2007
Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
Biopharmaceuticals FDA
 HSMN NewsFeed - 15 Aug 2007
Noven Completes Acquisition of JDS Pharmaceuticals
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 10 Aug 2007
FDA Grants Additional Six Months Marketing Exclusivity for the High Blood Pressure Medicine Diovan(R)
Biopharmaceuticals FDA
 HSMN NewsFeed - 6 Aug 2007
XOMA Appoints Steven B. Engle President, Chief Executive Officer and Director
Biopharmaceuticals Personnel
 HSMN NewsFeed - 23 Jul 2007
QLT announces FDA filing and review of Aczone(TM) labeling supplement for removal of blood screening requirement
Biopharmaceuticals Dermatology FDA
 HSMN NewsFeed - 10 Jul 2007
Noven to Acquire JDS Pharmaceuticals, Expanding Business Model & Broadening Product Pipeline
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 22 Jun 2007
FDA Approves Novartis Consumer Health, Inc.'s Over-the-Counter THRIVE(TM) Gum for Cessation of Smoking
Biopharmaceuticals FDA
 HSMN NewsFeed - 21 Jun 2007
Exforge(R) Receives Final US Approval as New and Powerful Treatment Option for Patients With High Blood Pressure
Biopharmaceuticals FDA
 HSMN NewsFeed - 11 Jun 2007
US Court Allows Teva to Resume US Sales of Its Generic Version of Lotrel
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 29 May 2007
US Court Continues to Prevent Teva From Shipping Any Additional Generic Copies of the High Blood Pressure Medicine Lotrel
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 29 May 2007
QLT USA, Inc. files Aczone(TM) labeling supplement for removal of blood screening requirement
Biopharmaceuticals Dermatology Regulatory
 HSMN NewsFeed - 21 May 2007
Watson Enters Into Agreement to Permit Sandoz to Launch Metoprolol Succinate Extended-Release 50 mg Tablets; Relinquishes 180-Day Market Exclusivity
Biopharmaceuticals Generics
 HSMN NewsFeed - 21 May 2007
Clinical Trial Data for Perforomist(TM) (Formoterol Fumarate) Inhalation Solution Presented at International ATS Conference
Biopharmaceuticals
 HSMN NewsFeed - 21 May 2007
Single-Tablet Combination of Tekturna(R) and Diuretic, an Important New Option for People With High Blood Pressure, Accepted for Review in U.S.
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 11 May 2007
FDA Approves Dey, L.P.'s Perforomist(TM) (Formoterol Fumarate) Inhalation Solution for Maintenance Treatment of COPD
Biopharmaceuticals FDA
 HSMN NewsFeed - 10 May 2007
Molecular Insight Pharmaceuticals, Inc. Initiates Azedra(TM) Therapeutic Trial in Neuroendocrine Cancer Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 May 2007
Once-yearly Reclast(R) Significantly Reduced Bone Fractures in Women with Postmenopausal Osteoporosis
Biopharmaceuticals Orthopaedic
 HSMN NewsFeed - 1 May 2007
QLT strengthens its expertise in ocular by adding David A. Saperstein M.D. as interim Chief Medical Officer and Paul L. Kaufman M.D. as Head of the Ocular Scientific Advisory Board
Biopharmaceuticals Personnel
 HSMN NewsFeed - 30 Apr 2007
Newly Published Study Reveals Femara(R) Improves Chances for Harder to Treat Early Breast Cancer Relapse in Postmenopausal Women
Biopharmaceuticals Oncology
 HSMN NewsFeed - 25 Apr 2007
QLT announces that CHMP will recommend to the European Commission that occult indication be deleted from the Visudyne(R)label in European Union
Biopharmaceuticals Ophthalmology Regulatory
 HSMN NewsFeed - 17 Apr 2007
Reclast(R) Receives US Approval as a Highly Effective Treatment for Patients with Paget's Disease of the Bone
Biopharmaceuticals FDA
 HSMN NewsFeed - 16 Apr 2007
Boston Life Sciences Appoints Frank Bobe as Executive Vice President and Chief Business Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 12 Apr 2007
Positive Results Prompt US National Cancer Institute to Make Gleevec(R) Available To Patients in Post-Surgical GIST Study
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Apr 2007
XOMA Announces Clinical Trial Plans for XOMA 052 in Type 2 Diabetes
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 12 Apr 2007
Novartis Completes Its Business Portfolio Restructuring, Divesting Gerber for USD 5.5 Billion to Nestlé
Biopharmaceuticals Personnel
 HSMN NewsFeed - 9 Apr 2007
Innovative Pulmonary and PEGylation-Based Therapeutic Product Development Drives Business Strategy of Nektar Therapeutics
Biopharmaceuticals Personnel
 HSMN NewsFeed - 4 Apr 2007
Protemix Raises US$14.5 Million in First Close of Series A Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 30 Mar 2007
Novartis Suspends US Marketing and Sales of Zelnorm(R) in Response to Request from FDA
Biopharmaceuticals Gastroenterology FDA
 HSMN NewsFeed - 28 Mar 2007
Rincon Pharmaceuticals Appoints Dr. Peter B. Heifetz as Chief Scientific Officer, Drs. Jacqueline J. Johnson and Alan J. Lewis to Board of Directors, and Drs. Katherine S. Bowdish and Mich B. Hein to Scientific Advisory Board
Biopharmaceuticals Personnel
 HSMN NewsFeed - 26 Mar 2007
Tekturna(R), First New Type of High Blood Pressure Medicine in a Decade, Provides Additional Blood Pressure Reduction When Used With Diovan(R)
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 6 Mar 2007
Tekturna(R) - The First New Type of High Blood Pressure Medicine In More Than a Decade - Receives Its First Approval in the US
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 5 Mar 2007
QLT Settles MEEI Lawsuit With Respect to the '303 Patent
Biopharmaceuticals Ophthalmology Litigation
 HSMN NewsFeed - 26 Feb 2007
XOMA Announces Planned Retirement of Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 14 Feb 2007
Clinical Data Supporting Development of ChemGenex's Ceflatonin(R) in Imatinib-Resistant CML Published in Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Feb 2007
Schering-Plough Cites Today's Anacor Agreement as Latest in Series of Deals
Biopharmaceuticals Licensing
 HSMN NewsFeed - 22 Dec 2006
Exforge(R) Receives US Regulatory Approval as a New and Highly Effective Treatment Option for Patients with High Blood Pressure
Biopharmaceuticals FDA
 HSMN NewsFeed - 11 Dec 2006
Pivotal Submission Data Shows Tasigna(R) Achieved Impressive Response Rates In Chronic Myeloid Leukemia Patients No Longer Helped by Gleevec(R)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 6 Dec 2006
New Evidence Reinforces Efficacy and Tolerability of Galvus(R) as a New Once-Daily Oral Treatment Option for Patients With Type 2 Diabetes
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 1 Dec 2006
Eligard(R) six-month formulation approved in Germany
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 14 Nov 2006
ChemGenex Announces Granting of Fast Track Status for Ceflatonin(R) by FDA
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 23 Oct 2006
New Data for Zelnorm(R) Demonstrate Relief of Multiple Symptoms of Dysmotility-Type Dyspepsia
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 20 Oct 2006
FDA Approves Prescription Zaditor(R) for Over-The-Counter Relief From Itchy Eyes
Biopharmaceuticals Ophthalmology FDA
 HSMN NewsFeed - 19 Oct 2006
Gleevec(R) Approved in the US for Five Rare Life-Threatening Disorders With Limited Treatment Options
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 11 Oct 2006
Novartis Launches 'GALIANT' Study Comparing the Investigational Drug Galvus(R) and a Leading Class of Oral Anti-Diabetic Medicines
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 28 Sep 2006
New Data for FTY720 -- Aiming to Become the First Orally Effective Multiple Sclerosis Treatment -- Show Sustained Benefits Over Two Years
Biopharmaceuticals Neurology
 HSMN NewsFeed - 16 Sep 2006
Once-Yearly Reclast(R)* Demonstrates Highly Significant Fracture Risk Reductions in the Treatment of Postmenopausal Osteoporosis, New Study Shows
Biopharmaceuticals
 HSMN NewsFeed - 7 Sep 2006
Baxter Names Peter Nicklin Corporate Vice President and President, Baxter Europe
Biopharmaceuticals Devices Personnel
 HSMN NewsFeed - 6 Sep 2006
XOMA's NEUPREX(R) Granted Orphan Status in Europe
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 19 Jul 2006
Exelon(R) Patch, the first transdermal therapy for Alzheimer's disease, may provide a promising new approach to treatment
Biopharmaceuticals Neurology
 HSMN NewsFeed - 10 Jul 2006
Human Genome Sciences Names Timothy C. Barabe Senior Vice President and Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 6 Jul 2006
Vanda Pharmaceuticals Names Dr. Paolo Baroldi Chief Medical Officer
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 28 Jun 2006
FDA Approves SPRYCEL(TM) (dasatinib) With Two Indications
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 27 Jun 2006
The U.S. Food and Drug Administration Approves Exelon(R) (rivastigmine tartrate) as the First Medication Indicated to Treat Parkinson's Disease Dementia
Biopharmaceuticals FDA Neurology
 HSMN NewsFeed - 25 May 2006
QLT strengthens corporate development and legal functions with the appointment of Peter J. O'Callaghan as Senior Vice President, Corporate Development and General Counsel
Biopharmaceuticals Personnel
 HSMN NewsFeed - 23 May 2006
New Data Show Overactive Bladder Therapy Enablex(R) Does Not Impair Memory Function Compared to Frequently Used Alternative
Biopharmaceuticals Urology Neurology
 HSMN NewsFeed - 23 May 2006
NICE Initial Recommendation: One Step Closer to Backing Aromatase Inhibitor Treatment for Women With Early Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 May 2006
Study Reveals Zelnorm(R) May Be a Safe and Effective Treatment for Additional Group of IBS Patients With a Mixed Bowel Pattern
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 19 May 2006
Biovail to Promote Novartis' Lescol(R) Franchise in Canada; Lescol(R) Provides Treatment Option for Patients Who Need a Statin to Reduce Cardiovascular Risk
Biopharmaceuticals
 HSMN NewsFeed - 19 May 2006
Diovan(R) (valsartan) the First Blood Pressure Medication in a Large-Scale Clinical Trial to Lower C-Reactive Protein, an Important Marker of Inflammation
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 17 May 2006
FDA Advisory Committee Recommends Approval of Exelon(R) (rivastigmine tartrate) in the Treatment of Dementia Associated with Parkinson's Disease
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 17 May 2006
MorphoSys and Schering-Plough Sign R&D Agreement
Biopharmaceuticals
 HSMN NewsFeed - 17 May 2006
Novartis Announces Efficacy Data on New Investigational High Blood Pressure Therapies at The American Society of Hypertension Annual Meeting
Biopharmaceuticals
 HSMN NewsFeed - 15 May 2006
ESBATech AG Announces Appointment of James Egan as Chief Business Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 10 May 2006
Axcan Pharma appoints new Senior Vice President and Chief Scientific Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 10 May 2006
Five years after approval, Gleevec underscores the promise of targeted therapy to provide sustained disease control
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 May 2006
Novartis Awarded Up to USD220 Million by U.S. Department of Health and Human Services for Development of Cell Culture-Derived Influenza Vaccine
Biopharmaceuticals
Return to NewsFeed  

 Additional items found! 204

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 204 additional stories matching:
Novartis AG
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.